民生证券股份有限公司 关于苏州近岸蛋白质科技股份有限公司 2024 年度募集资金存放与实际使用情况的专项核查意见 民生证券股份有限公司（以下简称"民生证券"或"保荐机构"）作为苏州近岸 蛋白质科技股份有限公司（以下简称"近岸蛋白"或"公司"）首次公开发行股票并 在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券 交易所上市公司自律监管指引第 11 号—持续督导》《上市公司监管指引第 2 号 —上市公司募集资金管理和使用的监管要求》《上海证券交易所科创板股票上市 规则》《上海证券交易所上市公司自律监管指引第 1 号—规范运作》等有关规定， 对近岸蛋白 2024 年度募集资金的存放和实际使用情况进行了专项核查，核查情 况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意苏州近岸蛋白质科技股份有限公司首 次公开发行股票注册的批复》证监许可[2022]1626 号文件核准，公司向社会公开 发行人民币普通股（A 股）1,754.3860 万股，每股发行价为 106.19 元，应募集资 金总额为人民币 186,298.24 万元，根据有关规定扣除发行费用 12,078.66 万元后， 实 ...

关于苏州近岸蛋白质科技股份有限公司 专项核查意见 民生证券股份有限公司（以下简称"民生证券"或"保荐机构"）作为苏州近岸 蛋白质科技股份有限公司（以下简称"近岸蛋白"或"公司"）首次公开发行股票并 在科创板上市及持续督导的保荐机构，根据《证券发行上市保荐业务管理办法》 《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《上 海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管 规则适用指引第 1 号——规范运作》及《科创板上市公司持续监管办法（试行）》 等有关规定，对近岸蛋白变更部分募投项目实施地点及募投项目延期事项进行了 审慎核查，核查情况及核查意见如下： 民生证券股份有限公司 变更部分募投项目实施地点及募投项目延期的 一、募集资金的基本情况 经中国证券监督管理委员会于 2022 年 7 月 25 日出具的《关于同意苏州近岸 蛋白质科技股份有限公司首次公开发行股票注册的批复》（证监许可[2022]1626 号）批准，公司首次公开发行人民币普通股（A 股）股票（以下简称"本次发行"） 17,543,860 股，每股发行价格为人民币 106.19 元，募集资金总额为人民币 ...

专项审核报告 2024 年度营业收入扣除情况的 苏州近岸蛋白质科技股份有限公司 容诚专字[2025]200Z0649 号 容诚会计师事务所(特殊普通合伙) 中国·北京 容诚会计师事务所（特殊普通合伙） 总所：北京市西城区阜成门外大街 22 号 1 幢 10 层 1001-1 至 1001-26) TEL:010-6600 1391 FAX:010-6600 1392 E-mail:bj@rsmchina.com.cn https://www.rsm.global/china/ 关于苏州近岸蛋白质科技股份有限公司 2024 年度营业收入扣除情况的专项审核报告 容诚专字[2025]200Z0649 号 苏州近岸蛋白质科技股份有限公司全体股东： 我们接受委托，按照中国注册会计师审计准则审计了苏州近岸蛋白质科技股 份有限公司（以下简称近岸蛋白）2024 年度财务报表，并于 2025 年 4 月 26 日出 具了容诚审字[2025]200Z2351 号的无保留意见审计报告。在此基础上我们审核了 后附的近岸蛋白管理层编制的《苏州近岸蛋白质科技股份有限公司 2024 年度营业 收入扣除情况表》（以下简称营业收入扣除情况表） ...

审计报告 苏州近岸蛋白质科技股份有限公司 容诚审字[2025]200Z2351 号 容诚会计师事务所(特殊普通合伙) 中国·北京 目 录 | 序号 | 内 | 容 | 页码 | | --- | --- | --- | --- | | 1 | 审计报告 | | 1-6 | | 2 | 合并资产负债表 | | 1 | | 3 | 合并利润表 | | 2 | | 4 | 合并现金流量表 | | 3 | | 5 | 合并所有者权益变动表 | | 4-5 | | 6 | 母公司资产负债表 | | 6 | | 7 | 母公司利润表 | | 7 | | 8 | 母公司现金流量表 | | 8 | | 9 | 母公司所有者权益变动表 | | 9-10 | | 10 | 财务报表附注 | | 11-113 | 审 计 报 告 容诚会计师事务所(特殊普通合伙) 总所：北京市西城区阜成门外大街 22 号 1 幢 10 层 1001-1 至 1001-26 TEL: 010-6600 1391 FAX: 010-6600 1392 E-mail:bj@rsmchina.com.cn https//WWW.rsm.global/chin ...

2024 年度独立董事述职报告 宋夏云 本人作为苏州近岸蛋白质科技股份有限公司（以下简称"公司"）的独立董事， 2024 年度本人严格按照《中华人民共和国公司法》（下称"《公司法》"）、《中 华人民共和国证券法》（下称"《证券法》"）、《上市公司治理准则》等法律法 规及上交所的各项规定及《苏州近岸蛋白质科技股份有限公司章程》（以下简称 "《公司章程》"）、《苏州近岸蛋白质科技股份有限公司独立董事工作制度》的 规定，在工作中勤勉、尽责地履行董事职责和义务，注重与董事会其他董事、监事 会、经理层成员的密切、有效沟通，及时、全面、深入地了解公司运营情况和董事 会决议执行情况，亲自出席董事会及各专门委员会会议，认真审议各项议案，独立、 客观、公正地发表意见，充分发挥独立董事的作用，促进董事会及各专门委员会的 规范运作和公司治理水平的不断提高，有效维护公司全体股东尤其是中小股东的合 法权益。现将2024 年度履行独立董事职责情况报告如下： 一、独立董事的基本情况 （一）个人工作履历、专业背景以及兼职情况 宋夏云先生，1969 年 6 月出生，中国国籍，无境外永久居留权。2006 年毕业于 上海财经大学会计学专业，博士学 ...

苏州近岸蛋白质科技股份有限公司 2024 年度独立董事述职报告 金坚 本人作为苏州近岸蛋白质科技股份有限公司（以下简称"公司"）的独立董事， 2024 年度本人严格按照《中华人民共和国公司法》（下称"《公司法》"）、《中 华人民共和国证券法》（下称"《证券法》"）、《上市公司治理准则》等法律法 规及上交所的各项规定及《苏州近岸蛋白质科技股份有限公司章程》（以下简称 "《公司章程》"）、《苏州近岸蛋白质科技股份有限公司独立董事工作制度》的 规定，在工作中勤勉、尽责地履行董事职责和义务，注重与董事会其他董事、监事 会、经理层成员的密切、有效沟通，及时、全面、深入地了解公司运营情况和董事 会决议执行情况，亲自出席董事会及各专门委员会会议，认真审议各项议案，独立、 客观、公正地发表意见，充分发挥独立董事的作用，促进董事会及各专门委员会的 规范运作和公司治理水平的不断提高，有效维护公司全体股东尤其是中小股东的合 法权益。现将2024 年度履行独立董事职责情况报告如下： 一、独立董事的基本情况 金坚先生，1960 年 5 月出生，中国国籍，无境外永久居留权。1996 年毕业于苏 州医学院内科学（血液病）专业，博士学历。1 ...

苏州近岸蛋白质科技股份有限公司 2024 年度独立董事述职报告 张宗新 本人作为苏州近岸蛋白质科技股份有限公司（以下简称"公司"）的独立董事， 2024 年度本人严格按照《中华人民共和国公司法》（下称"《公司法》"）、《中 华人民共和国证券法》（下称"《证券法》"）、《上市公司治理准则》等法律法 规及上交所的各项规定及《苏州近岸蛋白质科技股份有限公司章程》（以下简称 "《公司章程》"）、《苏州近岸蛋白质科技股份有限公司独立董事工作制度》的 规定，在工作中勤勉、尽责地履行董事职责和义务，注重与董事会其他董事、监事 会、经理层成员的密切、有效沟通，及时、全面、深入地了解公司运营情况和董事 会决议执行情况，亲自出席董事会及各专门委员会会议，认真审议各项议案，独立、 客观、公正地发表意见，充分发挥独立董事的作用，促进董事会及各专门委员会的 规范运作和公司治理水平的不断提高，有效维护公司全体股东尤其是中小股东的合 法权益。现将2024 年度履行独立董事职责情况报告如下： 一、独立董事的基本情况 （一）个人工作履历、专业背景以及兼职情况 张宗新先生，1972 年 3 月出生，中国国籍，无境外永久居留权。2002 年毕业于 ...

Financial Performance - The company reported a net profit attributable to shareholders of the listed company and the parent company for 2024 as negative, thus not meeting the conditions for profit distribution[6]. - The board of directors approved a profit distribution plan for 2024, which includes no cash dividends, no bonus shares, and no capital reserve transfer to increase share capital[6]. - The company has not achieved profitability since its listing[4]. - The company reported a revenue of ¥127,555,134.78 for 2024, a decrease of 16.73% compared to the previous year[23]. - The net profit attributable to shareholders decreased by 523.68% to -¥54,416,282.10 in 2024[23]. - The cash flow from operating activities dropped by 80.75% to ¥13,315,815.89, primarily due to a decline in sales revenue[26]. - Basic earnings per share fell to -¥0.78, a decline of 533.33% compared to the previous year[24]. - The weighted average return on net assets decreased by 3.12 percentage points to -2.53%[25]. - Total assets at the end of 2024 were ¥2,218,110,499.82, a decrease of 3.51% from the previous year[23]. - The company’s net assets attributable to shareholders were ¥2,101,667,719.87, down by 3.97% year-on-year[23]. - The revenue excluding non-core business income decreased by 16.90% to ¥126,927,351.41[23]. - The company achieved operating revenue of ¥127,555,134.78, a decrease of 16.73% compared to the same period last year[149]. - The gross margin decreased by 13.28 percentage points to 62.41%[156]. - Revenue from domestic sales was 122,042,857.92 million, down 18.64%, with a gross margin of 62.05%[156]. - Revenue from overseas sales increased significantly, with a growth rate of 76.32%, but the gross margin decreased by 3.65 percentage points to 70.52%[156]. Operational Strategies - The company plans to repurchase shares through centralized bidding in 2024[6]. - The company is implementing cost optimization strategies aimed at improving operational efficiency and increasing profit margins by G%[13]. - The company is actively seeking investment and acquisition opportunities related to its main business to enhance existing operations and integrate upstream and downstream resources[190]. - The company is planning to invest approximately $50 million in research and development for new product lines[199]. - The company is implementing new strategies to enhance operational efficiency, targeting a 5% reduction in costs[199]. - The company aims to enhance its protein technology and application solutions, focusing on innovation to provide efficient raw materials and tools for the biopharmaceutical industry[184]. - The company intends to expand its market share by increasing its business team and enhancing its marketing network, while also optimizing its sales channels to improve customer engagement[187]. - The company is focused on enhancing its technological capabilities to stay competitive in the biotechnology industry[200]. Research and Development - The company is investing in R&D, with a budget allocation of E million for the development of next-generation products and technologies[13]. - The company's R&D expenditure as a percentage of revenue increased to 39.14%, up by 9.9 percentage points from the previous year[25]. - R&D expenditure reached 49.92 million yuan, with over 300 new products and 14 new patents granted during the reporting period[37]. - The total R&D investment for the year reached ¥49,922,930.62, an increase of 11.46% compared to the previous year[119]. - The company has developed 23 core technologies and established 7 comprehensive technology platforms, enhancing its competitive edge in various biological fields[129]. - The company has launched multiple GMP-grade RNA-related products to meet differentiated innovation needs in the downstream market[45]. - The company has developed over 10,000 recombinant proteins, antibodies, and RNA-related products, providing comprehensive solutions for antibody drugs, cell therapy, gene therapy, and RNA vaccine clients[132]. - The company has established a dedicated protein research institute to enhance its R&D capabilities[200]. Market Expansion - The company is exploring market expansion opportunities in regions B and C, targeting a potential market size of D billion[13]. - The company is actively pursuing market expansion strategies, aiming to increase its market share in the biotechnology sector[200]. - Future guidance indicates a commitment to sustainable growth, with a focus on enhancing shareholder value through strategic investments and innovation[14]. - The company has completed a strategic acquisition of a smaller competitor, which is expected to increase market share by 10%[199]. - The company is exploring partnerships with key industry players to leverage synergies and enhance product offerings[199]. Governance and Compliance - The company has established a governance framework consisting of the shareholders' meeting, board of directors, supervisory board, and senior management, ensuring clear responsibilities and coordination[193]. - There were no significant differences between the company's governance and the regulations set by the China Securities Regulatory Commission[193]. - The company has not faced any issues regarding independence or autonomous operational capabilities from its controlling shareholders[193]. - The company has not reported any changes in the implementation of differential voting rights during the reporting period[196]. - The total pre-tax remuneration for the chairman and general manager, Zhu Huaxing, was CNY 878,400[197]. - The total pre-tax remuneration for the vice general manager and core technical personnel, Wang Yingming, was CNY 551,300[197]. - The total pre-tax remuneration for the vice general manager, Zhao Yujian, was CNY 143,700[197]. - The total pre-tax remuneration for the board secretary and vice general manager, Wang Duqiang, was CNY 460,800[197]. Challenges and Risks - The company has detailed the potential risk factors it may face during operations in the report[4]. - The company faces risks related to new product development and technology iteration, which may lead to uncertainties in market competitiveness[139]. - The company maintains a high inventory level, which poses a risk of inventory impairment due to long sales cycles[145]. - The company faces intensified market competition, particularly from established foreign brands in the recombinant protein market[144]. - The macroeconomic environment and overall slowdown in the biopharmaceutical industry may impact market demand and production costs[148]. User Engagement and Market Response - User data showed an increase in active users, reaching Z million, which is a W% increase year-over-year[14]. - The management reported a significant increase in user data, with a growth rate of 25% year-over-year in active users[199]. - User engagement metrics have improved, with a 30% increase in user retention rates[199]. - The company plans to increase marketing personnel and expand customer coverage to enhance customer loyalty and promote in emerging markets[157].

Financial Performance - The company's operating revenue for Q1 2025 was ¥33,444,619.29, representing a 28.20% increase compared to ¥26,087,054.66 in the same period last year[4] - The net profit attributable to shareholders was -¥11,808,403.41, a significant decline from -¥2,630,474.68 in the previous year, indicating a worsening financial performance[4] - The basic and diluted earnings per share were both -¥0.17, reflecting a decline from -¥0.04 in the same period last year[4] - The weighted average return on equity was -0.56%, a decrease of 0.44 percentage points from -0.12% in the previous year[4] - Net loss for Q1 2025 was CNY 11,808,403.41, compared to a net loss of CNY 2,630,474.68 in Q1 2024, indicating a significant increase in losses[19] - Operating profit for Q1 2025 was reported at CNY -15,553,406.18, worsening from CNY -4,997,646.70 in Q1 2024[18] Cash Flow - The net cash flow from operating activities was -¥13,275,293.49, a decrease of 275.64% compared to ¥7,558,148.81 in the same period last year[4] - Cash flow from operating activities in Q1 2025 was CNY 30,084,732.40, down from CNY 39,202,846.49 in Q1 2024, reflecting a decrease of 23.2%[21] - Cash inflow from operating activities totaled $30,995,341.75, while cash outflow was $44,270,635.24, leading to a negative cash flow[22] - The net increase in cash and cash equivalents for the period was $40,360,538.09, a significant decrease from $529,041,189.60 in the previous period[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,214,208,460.08, a slight decrease of 0.18% from ¥2,218,110,499.82 at the end of the previous year[5] - Total liabilities increased to CNY 121,652,748.93 from CNY 116,442,779.95, marking a rise of 4.0%[16] - The company's equity attributable to shareholders was ¥2,092,555,711.15, down 0.43% from ¥2,101,667,719.87 at the end of the previous year[5] Research and Development - Research and development expenses totaled ¥13,318,794.20, up 21.07% from ¥11,000,774.78, accounting for 39.82% of operating revenue[5] - Research and development expenses for Q1 2025 were CNY 13,318,794.20, up 21.0% from CNY 11,000,774.78 in Q1 2024, indicating a focus on innovation[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 5,887[9] - There were no significant changes in the top 10 shareholders or their shareholding percentages compared to the previous period[11] - The company’s repurchase account held 360,337 shares, accounting for 0.51% of the total share capital[11] Government Support - The company received government subsidies amounting to ¥275,849.48, which are closely related to its normal business operations[6] Inventory and Receivables - Accounts receivable rose to ¥62,916,585.14 from ¥59,959,090.49, indicating an increase of about 4.9%[14] - Inventory decreased to ¥70,609,687.64 from ¥76,083,001.99, showing a reduction of about 7.1%[14] - The total current assets decreased slightly to ¥1,934,663,394.24 from ¥1,956,275,857.23, reflecting a decline of approximately 1.1%[14] - The company reported a significant increase in receivables financing, which rose to ¥5,988,871.00 from ¥2,061,250.00, marking an increase of about 190%[14] Future Outlook - The company plans to implement new accounting standards starting in 2025, which may affect future financial reporting[23] - The company has not disclosed any new product developments or market expansion strategies during the reporting period[12]